For years, the story of American healthcare has read like an obituary for small, independent medical practices. Faced with shrinking reimbursements, staffing shortages, and rising administrative burden, many physicians traded autonomy for stability, selling to health systems or private equity. Yet beneath the consolidation headlines, a quiet rebellion is taking shape. Across the country, small specialty and multi-site practices are not only surviving but posting strong margi

All around you, Healthcare leadership continues to lean on familiar solutions: more education, more empowerment, more reminders to improve adherence. It sounds polite, nonthreatening, and promising. But it’s also a comfortable excuse that obscures a deeper, systemic failure. Because the truth is: medication adherence—our most basic measure of patient engagement—remains stubbornly low. Despite decades of well-meaning interventions, the problem persists. This isn’t a patient fa

Traditionally, and still in many practices today, some of the most important parts of a primary care visit happen after the patient leaves the exam room. Diagnosis is often delayed, follow-up decisions are disconnected from the visit itself, and early opportunities for intervention can be missed.

Weight-loss drugs are among the hottest products in medicine. GLP-1 receptor agonists such as Ozempic and Wegovy are so popular that demand has routinely exceeded supply. Into that gap, a booming market for compounded versions has emerged. One that authors from The Journal of the American Medical Association (JAMA) and JAMA Health Forum warn is largely unregulated, inconsistently manufactured, and increasingly risky.

When most Americans think of health insurance, they picture their employer plan or marketplace coverage. Yet behind the scenes, two massive public programs — Medicaid and Medicare Advantage — shape the foundation for how coverage works across the entire system.